The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PFE | -2.8% | -9.62% | -2% | +31,605% |
| S&P | +13.35% | +91.49% | +13.87% | +6,892% |
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Pfizer just gave income investors four reasons to like its juicy dividend even more.
These healthcare stocks are making strides in very important ways.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $16.65B | -5.9% |
| Gross Profit | $11.18B | 3.8% |
| Gross Margin | 67.15% | 6.3% |
| Market Cap | $144.87B | -11.7% |
| Market Cap / Employee | $1.79M | 0.0% |
| Employees | 81K | -8.0% |
| Net Income | $3.55B | -20.8% |
| EBITDA | $7.19B | 7.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.34B | 23.0% |
| Accounts Receivable | $14.26B | -1.3% |
| Inventory | 11.5K | -2.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $57.41B | -1.0% |
| Short Term Debt | $4.30B | -55.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.58% | 2.6% |
| Return On Invested Capital | 11.32% | -1.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.00B | -34.0% |
| Operating Free Cash Flow | $4.60B | -31.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.86 | 18.29 | 12.87 | 13.85 | -64.58% |
| Price to Book | 1.63 | 1.63 | 1.53 | 1.63 | -12.66% |
| Price to Sales | 2.38 | 2.30 | 2.16 | 2.16 | -21.68% |
| Price to Tangible Book Value | -4.14 | -4.02 | -4.30 | -4.39 | 12.36% |
| Price to Free Cash Flow TTM | 468.42 | 87.67 | 49.37 | 202.63 | - |
| Enterprise Value to EBITDA | 26.36 | 30.29 | 35.94 | 25.42 | -23.71% |
| Free Cash Flow Yield | 0.2% | 1.1% | 2.0% | 0.5% | - |
| Return on Equity | 9.1% | 8.6% | 12.2% | 10.6% | 134.37% |
| Total Debt | $66.99B | $62.11B | $61.80B | $61.71B | -8.85% |
A look at stock market news.
Investors knew that a vaccine was coming, so why did the market react the way it did?
Some of our favorite banks and real estate stocks are having their best rallies in years.
First, it raised some spinoff speculation. Second, it's in an intriguing tussle with J&J that could affect the biosimilars market for everyone.
PFE earnings call for the period ending December 31, 2024.
PFE earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
